Glaxosmithkline Pharmaceuticals Limited · NSE:GLAXO
Glaxosmithkline Pharmaceuticals — Investor Presentation (March 2023)
27 slides from Glaxosmithkline Pharmaceuticals's investor presentation, Mar 16, 2023
Slide 1: Outcome of Analyst / Institutional Investor Meetings letter
GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 16th March 2023 To, BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Excha
Slide 2: Analysts' meet
Analysts' meet GlaxoSmithKline Pharmaceuticals Limited 16th March 2023 The session will begin at 4:30 pm (1ST) Participants are requested to remain on mute and raise their hand to ask a question ({ID gsk.com
Slide 3: Bhushan Akshikar, Managing Director
~ Bhushan Akshikar, Managing Director Mr. Bhusha n Akshikar has a successful track record of over 12 years in key leadership roles in GSK across India, Middle East, Russia CIS & Africa region. Before joining GSK, Bhusha n spent 15 yea rs with Janssen, Johnson & Johnson, in various commercial roles l
Slide 4: Juby Chandy, Chief Financial Officer
~ Juby Chandy, Chief Financial Officer Mr. Juby Chandy has a successful track record of over 14 years in key leadership roles in GSK across India, Singapore, Southeast Asia, Vietnam, Turkey, and the Middle East. GSK 16 Morch 2023 3
Slide 5: Agenda
~ Agenda Market overview GSK India overview Financial overview GSK
Slide 6: We unite science, technology and talent to get ahead of disease together
Our purpose We unite science, technology and talent to get ahead of disease together
Slide 7: The Indian Pharma market
~ The Indian Pharma market 5 yrCAGR Projected CAGR Contribution (15-20) (20-25) GROW TH DRI V ERS ll Cardiac • Vol.Gwth 9% • Price Gwth • N.I Gwth m Anti-infectlves 7% 5% 2.8 7% B Gastro Int estinal •• 2.3 1.9 4.3 2.5 4% 1.3 6% •li1 Anti Diabetic Respiratory : . ' 5.1 5.1 5.6 2.2 5.3 4.3 (§a,,;1m111
Slide 8: GSK Pharma Represented Market: Key TAs
~ GSK Pharma Represented Market: Key TAs GSK operates in ~20k Cr market and growing in double digits Al 4,mcr /4,ma ( wscr 3,223Cr 2,620Cr 2,037Cr J,602 Cr ua1c, 19%YoY 12% YoY 9%CAGR ••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••
Slide 9: GSK India Footprint
~ GSK India Footprint 2nd Rank M NC in I PM (2.6% Value share & -4% Volume share) 22 Contract Manufacturing 3700+ State-of-the-art Manufacturing unit Employees Organisations in Nashik, Maharashtra (68% of total Supply) *''* ̴ 200Mn ̴ patients on general immunisation sessions medicine portfolio/year
Slide 10: Manufacturing facility in Nashik
GSK GlaxoSmithKline Pharmaceuticals Limited's Manufacturing facility in Nashik
Slide 11: Where to play? How to win?
Where to play? General Medicines Vaccines Specialty Anti-infectives Derma Neosporin -- . -· ..........,...,_ ~~ SHINGRIX ~ BACTROBAN - ' ) HERPES ZOSTERVACCINE (RECOMBINANT, ADJUVANTED) NucALA Dermovate mepolizumab VM Ns and Hormones °"""""- Injection I00mglmL ELTROXIN coaa0cxCZS A --- Cutivate Betn
Slide 12: Our Portfolio
~ Our Portfolio Serving patients over decades with Quality brands Strong Portfolio Sold Every Second Ranked #l Brand in Indian Pharmaceutical AUGMENTIN' I Market 8 Units 2 Units of of Calpol Calpol ,_.,,_--..t-...t .. 4 of our brands in lPU Top 50 brandsof 1PM T-bact 6 Units of l Unit of Betnesol T
Slide 13: Continuing our strong footprint
~ Continuing our strong footprint Physical and Omnichannel presence A 50kottendonce ~ in SPMs/CMEs 2.7 Mn sessions on consumer website ~ ~ 300k+ HCPs covered by8 a480RepHQs teams A ~ ~10,000 Cities covered 2900+ strong field force 10 Mn e-mails @ ® 20k HCPs calls per 30 Mn 22k HCPs doy Touchpoints a
Slide 14: Our Strategic Focus
~ Our Strategic Focus Defend Launch Improve competitiveness by Protect market share & drive Deliver exceptional launches, Investing behind Key Brands in profit optimisation in starting with Shingrix GenMed&Vx Performance brands Evolve a culture where our people develop, thrive & do the right thing G
Slide 15: Contemporising our portfolio
~ Contemporising our portfolio Augmentin LCM to fight rising resistance in India: Launch of Augmentin ES Ji AMOXYCILLIN CALPOL650 → CALPOL 650+ with OPTIZORB AND POTASSIUM CLAVULANATE ORAL SUSPENSION IP 642.9 mg/ 5ml Co-amoxlclav 12.5 g/ 50 ml Calpol 650 0 WITH OPTIZORB FORMULATION Orig.............
Slide 16: Vaccines market yet to regain momentum
~ Vaccines market yet to regain momentum Focus brands gained MS despite a down market 39 37.9 38 37 36 35 34.1 • Focus Brands • Rest of Portfolio 34 33 Our Vaccines in NIP portfolio are getting 32 stabilised MS2021 MS2022 Focus brands gained 4% market share in 2022 Some key Vx to resume supply in 20
Slide 17: Vaccination Awareness Campaigns for Consumers
~ Vaccination Awareness Campaigns for Consumers Creating Awareness through Omnichannel presence (Digital, Mainline Media, PR) 6 in 1 campaign Why worry! - Vaccination compliance campaign When your baby can hit a six in one shot! X X -~ ~ Faisla Sahi Zindagi Sahi Reach: 30 Mn, Impressions: >3Bn (2 bo
Slide 18: Driving Awareness
~ Driving Awareness "SK ·~ Faisla Sahi ~ Zindagi Sahi GSK partnering with Kareena -~ Faisla Sahi Kapoor Khan (mom -~ Zirndagi Sahi ambassador) and Doctors to Drive compliance of annual flu vaccination in kids 1-5 years old rlci:td fur ititjh ,i;;v. d1iklr~ri. GSK 16 March 2023 17
Slide 19: Driving Awareness
~ Driving Awareness GSK ·~ Faisla Sahi ~ Zindagi Sahi ~ Faisla Sahi ·~ Zirndagi Sahi GSK partnering with Kareena Kapoor Khan (mom ambassador) and Doctors to drive compliance in toddlers aged l year+ in-clinics GSK 16 March 2023 18
Slide 20: Shingrix
~ Shingrix Our Vision : A world protected from Shingles SHINGRIX >90% of Adults >50 years old are infected with HERPES ZOSTER VACCINE virus that causes Shingles1 (RECOMBINANT, ADJUVANTED) l in 3 • Globally, vaccines growth was fueled by Shingrix registering GBP 3 Bn Estimated lifetime risk of Shingl
Slide 21: Shingrix: Creating a new Adult vaccine category in India
~ Shingrix : Creating a new Adult vaccine category in India India a key market for Shingrix 1st Non live, Only NON LIVE vaccine approved for Individuals ~50 years of age Approval for adults recombinant, >=50 years of age.1 adjuvanted vaccine ANTIGEN ADJVVANT against shingles with G\loooroteone (gl')
Slide 22: 2023 NLEM impacts pharma business, mitigation planned
2023 NLEM impacts pharma business, mitigation planned through various initiatives 2022 2023 33% 42% Key Highlights 2023 NLEM ➢ N LEM once in 5-year event; impacting 2023; Ceftum & T-Bact are new inclusions 67% 58% ➢ Shingrix Launch NLEM Impacted NLEM Impacted Not in Price Control ➢ Vx Stabilization
Slide 23: Focus on growing the top line; EBITDA evolution
~ Focus on growing the top line; EBITDA evolution Turnover EBITDA and Margins 1,200 25% FY23- FY25 1,000 20% 23% 800 20% High single digit 19% 15% 18% growth 600 16% 10% 400 5% 200 Volume driven growth - 2017-18 2018-19 2019-20 2020-21 2021-22 Est 2022-23 Est 2023-24 Est 2024-25 Est 2025-26 0% EBITD
Slide 24: GSK India Ambition 2023-28
~ GSK India Ambition 12023-28 Deliver Double digit growth to touch the lives of a billion Indians Deliver new launches to drive innovation growth Continue competitive performance with profitable growth in the base business Evolve a culture where our people develop, thrive & do the right thing Ambiti
Slide 25: Building trust in India
Building trust in India
Slide 26: Slide 26
Slide 27: Q&A
B com
GlaxoSmithKline Pharmaceuticals — Investor Presentation (March 2023) on 6ix